Q1 Earnings Estimate for DBVT Issued By HC Wainwright

DBV Technologies S.A. (NASDAQ:DBVT) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for DBV Technologies in a note issued to investors on Friday, March 27th. HC Wainwright analyst A. Fein expects that the company will post earnings per share of ($0.14) for the quarter. The consensus estimate for DBV Technologies’ current full-year earnings is ($7.05) per share. HC Wainwright also issued estimates for DBV Technologies’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.13) EPS and FY2030 earnings at $1.75 EPS.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.96). The firm had revenue of $0.64 million during the quarter, compared to analysts’ expectations of $1.06 million. DBV Technologies had a negative return on equity of 189.17% and a negative net margin of 2,606.83%.

Several other analysts also recently weighed in on DBVT. Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, December 17th. Citizens Jmp raised their target price on shares of DBV Technologies from $45.00 to $47.00 and gave the stock a “market outperform” rating in a report on Friday. Guggenheim reaffirmed a “buy” rating and issued a $51.00 target price on shares of DBV Technologies in a research note on Friday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of DBV Technologies in a report on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $38.65.

DBV Technologies Price Performance

Shares of NASDAQ DBVT opened at $20.00 on Monday. DBV Technologies has a one year low of $5.30 and a one year high of $26.18. The firm’s 50 day simple moving average is $21.58 and its two-hundred day simple moving average is $17.33. The stock has a market capitalization of $1.11 billion, a P/E ratio of -3.83 and a beta of -0.97.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vivo Capital LLC purchased a new stake in DBV Technologies in the 2nd quarter worth approximately $9,659,000. Artisan Partners Limited Partnership purchased a new position in shares of DBV Technologies during the third quarter valued at approximately $519,000. DLD Asset Management LP purchased a new position in shares of DBV Technologies during the third quarter valued at approximately $250,000. New York State Common Retirement Fund bought a new position in shares of DBV Technologies during the third quarter valued at approximately $34,000. Finally, Citadel Advisors LLC bought a new position in shares of DBV Technologies during the third quarter valued at approximately $220,000. Institutional investors own 71.74% of the company’s stock.

Key Headlines Impacting DBV Technologies

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: VIASKIN peanut patch nearing FDA submission — media coverage highlights management preparing for a BLA/approval pathway and positions the peanut patch as a potential near-term commercial catalyst. DBV Technologies sets stage for ‘swift’ success as breakthrough peanut patch nears FDA submission
• Positive Sentiment: Citizens Jmp raised its price target to $47 and assigned a “market outperform” rating, signaling strong analyst conviction and implying substantial upside from current levels. Citizens Jmp price target raise
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating and set a $51 price target, another high-end analyst endorsement that supports the bullish narrative around the peanut patch program. Guggenheim reiterates buy
• Positive Sentiment: Financial and operational update: DBV reports progress in toddler and child VIASKIN trials, strengthened leadership ahead of BLA submission, and disclosed cash of $194M plus $94M of additional proceeds (funding into Q2 2027) — improving near-term runway for regulatory activities. DBV Technologies Reports Full Year 2025 Financial Results and Business Update
• Neutral Sentiment: Regulatory/filing housekeeping — DBV filed its 2025 Form 10-K and Universal Registration Document (URD), making audited results and governance disclosures available to investors. This is procedural but important for due diligence. DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
• Negative Sentiment: Quarterly results significantly missed expectations: EPS of ($4.43) vs. consensus ($0.19) and revenue $0.64M vs. $1.06M expected — very wide losses and negative margins raise near-term valuation and funding-scenario concerns despite the stated cash runway. DBV Technologies quarterly earnings press release

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.